Related references
Note: Only part of the references are listed.Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
Jerald Sadoff et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine
Edward E. Walsh et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
COVID-19 mRNA vaccines: Platforms and current developments
Gabor Tamas Szabo et al.
MOLECULAR THERAPY (2022)
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults
Yuji Orito et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women
Tino F. Schwarz et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Repeated-Dose Toxicity, Biodistribution, and Shedding Assessments With a ChAd155 Respiratory Syncytial Virus Vaccine Candidate Evaluated in Rabbits and Rats
Alan H. Stokes et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2022)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis
You Li et al.
LANCET (2022)
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Frauke Muecksch et al.
NATURE (2022)
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
Siri Tahtinen et al.
NATURE IMMUNOLOGY (2022)
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy
Eric A. F. Simoes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Laura L. Hammitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Nirsevimab: a promising therapy for RSV
Priya Venkatesan
Lancet Microbe (2022)
Making COVID-19 mRNA vaccines accessible: challenges resolved
Sarfaraz K. Niazi
EXPERT REVIEW OF VACCINES (2022)
SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity
Joey Ming Er Lim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2022)
Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein
Sierra S. Beach et al.
JOURNAL OF VIROLOGY (2022)
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
Beate Schmoele-Thoma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Jinyi Tang et al.
SCIENCE IMMUNOLOGY (2022)
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Advances in COVID-19 mRNA vaccine development
Enyue Fang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine
Elke Jordan et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults
Jerald Sadoff et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Neutrophils in respiratory syncytial virus infection: From harmful effects to therapeutic opportunities
Alireza Tahamtan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
Repeated Dose Toxicity Study and Developmental and Reproductive Toxicology Studies of a Respiratory Syncytial Virus Candidate Vaccine in Rabbits and Rats
Alan H. Stokes et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2021)
The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review
Jing Shan et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2021)
Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers
Renuka A. K. Kadali et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19
Stefania Capone et al.
MOLECULAR THERAPY (2021)
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Ezgi Hacisuleyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Tracy J. Ruckwardt et al.
LANCET RESPIRATORY MEDICINE (2021)
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Ugur Sahin et al.
NATURE (2021)
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
Kashif Ali et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus
Pierre-Louis Herve et al.
VACCINE (2021)
An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
Armando Zuniga et al.
NPJ VACCINES (2021)
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults
Antonios O. Aliprantis et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
Antonios O. Aliprantis et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults
Paola Cicconi et al.
CLINICAL INFECTIOUS DISEASES (2020)
Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children
Ruth A. Karron et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children
Elizabeth J. McFarland et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children
Elizabeth J. McFarland et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial
Nathaly Samy et al.
VACCINE (2020)
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection
Amy S. Espeseth et al.
NPJ VACCINES (2020)
The journey to a respiratory syncytial virus vaccine
Asuncion Mejias et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2020)
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years
Kristi Williams et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
A serological assay to detect SARS-CoV-2 seroconversion in humans
Fatima Amanat et al.
NATURE MEDICINE (2020)
Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
Leslie van der Fits et al.
NPJ VACCINES (2020)
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
M. Pamela Griffin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial
Pauline Verdijk et al.
VACCINE (2020)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus
Jessica Marcandalli et al.
CELL (2019)
Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
Christopher A. Green et al.
JOURNAL OF INFECTION (2019)
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Piotr S. Kowalski et al.
MOLECULAR THERAPY (2019)
Respiratory syncytial virus entry and how to block it
Michael B. Battles et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study
Geert Leroux-Roels et al.
VACCINE (2019)
Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated
Coleen K. Cunningham et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
A proof of concept for structure-based vaccine design targeting RSV in humans
Michelle C. Crank et al.
SCIENCE (2019)
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial
Tino F. Schwarz et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
The biogenesis, biology and characterization of circular RNAs
Lasse S. Kristensen et al.
NATURE REVIEWS GENETICS (2019)
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
Aimin Tang et al.
NATURE COMMUNICATIONS (2019)
Local dornase alfa treatment reduces NETs-induced airway obstruction during severe RSV infection
Bart Cortjens et al.
THORAX (2018)
Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation
Eileen Goodwin et al.
IMMUNITY (2018)
A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials
Jiri Beran et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children
Elizabeth J. McFarland et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
Natalie I. Mazur et al.
LANCET INFECTIOUS DISEASES (2018)
mRNA vaccines - a new era in vaccinology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
Joseph B. Domachowske et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2018)
Molecular epidemiology of respiratory syncytial virus
Krisna N. A. Pangesti et al.
REVIEWS IN MEDICAL VIROLOGY (2018)
The great escape: how cationic polyplexes overcome the endosomal barrier
Tanja Bus et al.
JOURNAL OF MATERIALS CHEMISTRY B (2018)
Involvement and Possible Role of Eosinophils in Asthma Exacerbation
Kazuyuki Nakagome et al.
FRONTIERS IN IMMUNOLOGY (2018)
Neutrophil extracellular traps in immunity and disease
Venizelos Papayannopoulos
NATURE REVIEWS IMMUNOLOGY (2018)
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
M. Pamela Griffin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Cameron Griffiths et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Differential lower airway dendritic cell patterns may reveal distinct endotypes of RSV bronchiolitis
Aoife Kerrin et al.
THORAX (2017)
Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design
Timothy Pepini et al.
JOURNAL OF IMMUNOLOGY (2017)
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
Judith Falloon et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Qing Zhu et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin
Madhusudan Rajendran et al.
MBIO (2017)
Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
Iebe Rossey et al.
NATURE COMMUNICATIONS (2017)
Vaccine development for respiratory syncytial virus
Barney S. Graham
CURRENT OPINION IN VIROLOGY (2017)
Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods
Trevor R. F. Smith et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
Judith Falloon et al.
CLINICAL AND VACCINE IMMUNOLOGY (2017)
The Human Immune Response to Respiratory Syncytial Virus Infection
Clark D. Russell et al.
CLINICAL MICROBIOLOGY REVIEWS (2017)
Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease
Bart Cortjens et al.
JOURNAL OF PATHOLOGY (2016)
Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV
M. Gordon Joyce et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant
Judith Falloon et al.
VACCINE (2016)
Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV
M. Gordon Joyce et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus
April M. Killikelly et al.
SCIENTIFIC REPORTS (2016)
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
Morgan S. A. Gilman et al.
SCIENCE IMMUNOLOGY (2016)
Elevated IL-3 and IL-12p40 levels in the lower airway of infants with RSV-induced bronchiolitis correlate with recurrent wheezing
Pablo Bertrand et al.
CYTOKINE (2015)
Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen
Bert Schepens et al.
IMMUNOTHERAPY (2015)
Neutrophils in respiratory syncytial virus infection: A target for asthma prevention
Ruben J. Geerdink et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults
Christopher A. Green et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Joan O. Ngwuta et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children
Ruth A. Karron et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats
Myra N. Widjojoatmodjo et al.
VACCINE (2015)
Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33
Jordy Saravia et al.
PLOS PATHOGENS (2015)
Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates
Angiolo Pierantoni et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2015)
Epidemiological Characteristics and Immune Status of Children With Respiratory Syncytial Virus
Qing Ye et al.
JOURNAL OF MEDICAL VIROLOGY (2015)
Dual Proinflammatory and Antiviral Properties of Pulmonary Eosinophils in Respiratory Syncytial Virus Vaccine-Enhanced Disease
Yung-Chang Su et al.
JOURNAL OF VIROLOGY (2015)
Respiratory Syncytial Virus Fusion Protein Promotes TLR-4-Dependent Neutrophil Extracellular Trap Formation by Human Neutrophils
Giselle A. Funchal et al.
PLOS ONE (2015)
RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction
Rachael M. Liesman et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery
Helen O. McCarthy et al.
JOURNAL OF CONTROLLED RELEASE (2014)
A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Luis A. Brito et al.
MOLECULAR THERAPY (2014)
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Michael T. Brady et al.
PEDIATRICS (2014)
Innate Immune Dysfunction is Associated with Enhanced Disease Severity In Infants with Severe Respiratory Syncytial Virus Bronchiolitis
Cesar Mella et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Respiratory Syncytial Virus Modified by Deletions of the NS2 Gene and Amino Acid S1313 of the L Polymerase Protein Is a Temperature-Sensitive, Live-Attenuated Vaccine Candidate That Is Phenotypically Stable at Physiological Temperature
Cindy Luongo et al.
JOURNAL OF VIROLOGY (2013)
Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age
Elissa Malkin et al.
PLOS ONE (2013)
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
Jason S. McLellan et al.
SCIENCE (2013)
The Neutrophilic Inflammatory Phenotype Is Associated With Systemic Inflammation in Asthma
Lisa G. Wood et al.
CHEST (2012)
The Small Hydrophobic Protein of the Human Respiratory Syncytial Virus Forms Pentameric Ion Channels
Siok-Wan Gan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Nonviral delivery of self-amplifying RNA vaccines
Andrew J. Geall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
Margarita Magro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers
Kurt A. Swanson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats
Myra N. Widjojoatmodjo et al.
VIROLOGY JOURNAL (2010)
Expression and purification of human respiratory syncytial virus recombinant fusion protein
Helen A. Arcuri et al.
PROTEIN EXPRESSION AND PURIFICATION (2008)
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines
Peter F. Wright et al.
VACCINE (2007)
Age-related difference in immune responses to respiratory syncytial virus infection in young children
Hai Lee Chung et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2007)
The histopathology of fatal untreated human respiratory syncytial virus infection
Joyce E. Johnson et al.
MODERN PATHOLOGY (2007)
Eosinophilic airway disorders
KA Scott et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans
PF Wright et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?
KM Beeh et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2006)
Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response
S Kristjansson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2005)
Suppression of RNA recognition by Toll-like receptors:: The impact of nucleoside modification and the evolutionary origin of RNA
K Karikó et al.
IMMUNITY (2005)
Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-κB, and proinflammatory cytokines
KM Spann et al.
JOURNAL OF VIROLOGY (2005)
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants
RA Karron et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Relationship between atopic status and nasal interleukin 10 and 11 levels in infants with respiratory syncytial virus bronchiolitis
HL Chung et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2005)
Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchlolitis
PS McNamara et al.
LANCET (2004)
Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein
MB Elliott et al.
JOURNAL OF VIROLOGY (2004)
Association of matrix protein of respiratory syncytial virus with the host cell membrane of infected cells
A Marty et al.
ARCHIVES OF VIROLOGY (2004)
Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis
PS McNamara et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2003)
Mucosal immunization with live recombinant bovine respiratory syncytial virus (BRSV) and recombinant BRSV lacking the envelope glycoprotein G protects against challenge with wild-type BRSV
U Schmidt et al.
JOURNAL OF VIROLOGY (2002)
Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo
MN Teng et al.
VIROLOGY (2001)
Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4+ T cells
SM Varga et al.
IMMUNITY (2001)
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus
MN Fleeton et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy
PF Wright et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
